Clinical Core

项目摘要 急性肾损伤(AKI)是一个公共卫生问题，直接影响临床和以患者为中心的预后。 以及医疗资源利用和政策。认识到AKI和AKI的突破性发现很少 这种情况的负担越来越大，UAB-UCSD O‘Brien临床核心(核心A)旨在减少 研究人员通过提供强大的 基础设施，以促进临床前、临床和行业研究人员之间的协作项目。核心A将 通过定制的项目网关提供多方面咨询、访问临床数据库、 现有的生物库，以及新的生物信息学和计算技术，如U-BRITE和 Nightingale与临床和转化科学合作的数字工作空间 两个机构的大数据协调和审问奖励(CTSA)方案，重点是 关于AKI中的个性化医疗。具体地说，Core A将促进电子产品的协作数字工作空间 健康记录(EHR)数据采集、转换、验证和询问。首要目标是 催化将长凳发现转化为影响人类AKI的应用。具体目标是 结构如下。在目标1中，我们将提供对AKI风险患者或AKI患者的临床数据的访问 咨询他们的使用情况。具体地说，我们将提供对先前临床研究的精选临床数据的访问 由核心A(目标1A)托管，并提供从电子病历获取新的协调一致的真实世界数据的途径，以支持 AKI的流行病学监测(例如AKI发病率、危险因素和结果)和新的临床研究， 包括但不限于AKI风险分类、分型和模拟试验(目标1B)。在目标2中，我们 将为有AKI风险或患有AKI的患者提供生物检疫剂，并为其使用提供咨询。具体来说， 我们将提供从核心A(AIM 2A)主持的先前研究中获取生物质谱学的途径。在Aim 2B中，我们将提供 一个新的平台，将有AKI风险或患有AKI的患者的生物谱系与EHR数据联系起来。核心A将拥有动态 与临床前核心、资源开发核心和 O‘Brien肾财团。在这项U54应用中，我们将建立在我们的专业知识和既定成功的基础上 通过我们目前资助的奥布莱恩中心P30奖进行展示。鉴于我们的承诺和专业知识， 我们相信，Core A将为不断增长的研究社区提供创新资源 与Aki相关的研究。

Project Summary Acute kidney injury (AKI) is a public health concern with direct impact on clinical and patient-centered outcomes, and healthcare resource utilization and policy. Recognizing the paucity of breakthrough discoveries in AKI and the growing burden of this condition, the UAB-UCSD O’Brien Clinical Core (Core A) is designed to reduce the barriers for investigators to conduct effective clinical and translational research by providing a robust infrastructure to promote collaborative projects across pre-clinical, clinical and industry researchers. Core A will provide multifaceted consultation through a customized Project Gateway, access to clinical databases, available biorepositories, and novel bioinformatics and computational technologies such as the U-BRITE and Nightingale collaborative digital workspaces in partnership with the Clinical and Translational Science Awards (CTSA) programs at both institutions for the harmonization and interrogation of big data with a focus on personalized medicine in AKI. Specifically, Core A will facilitate collaborative digital workspaces for electronic health record (EHR) data acquisition, transformation, validation, and interrogation. The overarching goal is to catalyze the translation of bench discoveries to applications that impact human AKI. The Specific Aims are structured as follows. In Aim 1, we will provide access to clinical data of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to curated clinical data from prior clinical studies hosted by Core A (Aim 1A) and provide access to new harmonized real-world data from the EHR to support epidemiological surveillance of AKI (e.g., AKI incidence, risk factors and outcomes) and novel clinical research, including but not limited to AKI risk-classification, sub-phenotyping, and simulated trials (Aim 1B). In Aim 2, we will provide access to biospecimens of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to biospecimens from prior studies hosted by Core A (Aim 2A). In Aim 2B we will provide a novel platform to link biospecimens of patients at risk for or with AKI with EHR data. Core A will have dynamic communications and collaborations with the Pre-Clinical Core, the Resource Development Core, and the O’Brien Kidney Consortium. In this U54 application, we will build upon our expertise and established successes demonstrated through our currently funded O’Brien Center P30 award. Given our commitment and expertise, we are confident that Core A will provide innovative resources to the growing research community interested in AKI-related research.